Quest Diagnostics stock gains as investors focus on growth and fair value

Published on 09/03/2026 at 18:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Quest Diagnostics stock is trading near analysts’ fair value estimates as investors weigh its growth prospects in diagnostics and broader healthcare, with the share price edging higher on September 3, 2026.

Makroaufnahme einer Laborzentrifuge mit Blutproben-Röhrchen und sichtbarer Plasmatrennung — Quest Diagnostics US74834L1008 fängt Makroaufnahme rotierender Zentrifuge mit getrennten Blutproben-Schichten in Röhrchen dramatisch ein, Illustration mit AI erstellt.

Quest Diagnostics stock (ISIN US74834L1008) was quoted around 240.72 USD as of September 3, 2026, with recent market data indicating a gain of about 1.9% on the day according to stock portal information.

Share price near fair value estimates

According to market commentary compiled by Simply Wall St on September 3, 2026, Quest Diagnostics is modeled to reach a fair value of about 245.87 USD per share based on earnings growth forecasts and cash flow assumptions, which is close to its current market price level.

The same analysis discusses how expanding networks in areas such as Alzheimer’s and kidney testing are expected to drive roughly 4.8% yearly revenue growth and an earnings increase of about 0.4 billion USD from a current base of around 1.1 billion USD, framing a medium term growth narrative for Quest Diagnostics.

Growth expectations and comparisons

In the growth scenario described by Simply Wall St, the projected 4.8% annual revenue increase suggests that over several years Quest Diagnostics could add a meaningful amount of top line sales compared with its existing revenue base, supporting the idea that the stock price around the mid 240 USD range is not far from estimated intrinsic value.

The analysis also highlights that if earnings rise by approximately 0.4 billion USD from about 1.1 billion USD, this would represent an increase of more than 36%, a substantial improvement in profitability that investors tracking Quest Diagnostics stock will weigh against risks such as reimbursement pressure and competitive dynamics in diagnostics.

Diagnostics and testing as business backbone

Quest Diagnostics generates much of its revenue from diagnostic testing services, including routine blood work, specialized assays and disease specific panels; expansion in areas like Alzheimer’s and kidney testing underscores how new clinical segments can support additional growth on top of its established diagnostics footprint.

For retail investors, the combination of a stock price near modeled fair value, moderate expected revenue growth and a potential uplift in earnings provides a balanced picture in which Quest Diagnostics stock reflects both the strengths of its diagnostic platform and the execution needed to realize forecasted gains.

Stock price snapshot and investor angle

With the share price around 240.72 USD on September 3, 2026 and short term technical readings close to that level, Quest Diagnostics stock remains within a range that analysts identify as near fair value, so future performance will likely depend on the company delivering on projected mid single digit revenue growth and the anticipated improvement in earnings.